{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:23:12Z","timestamp":1790673792092,"version":"4.1.0"},"reference-count":66,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:p>Dry eye disease (DED) is a common ocular condition that can impair vision and may adversely impact quality of life. Due to the inflammatory nature of this disorder, topical corticosteroids are an effective treatment option, particularly for moderate-to-severe DED when first-line treatments, such as ocular lubricants, are insufficient. Loteprednol etabonate (LE) is a retrometabolically designed corticosteroid with a low propensity to cause corticosteroid-related adverse effects, such as elevated intraocular pressure (IOP). This review was conducted to provide an assessment of published studies on the use of LE for treatment of inflammation associated with DED. Twelve prospective and 2 retrospective studies evaluating LE ophthalmic suspension 0.5% and 2 prospective studies evaluating LE ophthalmic gel 0.5% were identified. LE given as monotherapy or with artificial tears (AT) improved signs of DED, especially among patients with a more pronounced inflammatory component, and also improved DED symptoms compared to baseline and\/or control. Treatment with LE before cyclosporine A (CsA) therapy reduced stinging upon CsA initiation and provided more rapid relief of DED signs and symptoms than CsA plus AT alone. In patients with meibomian gland dysfunction, LE alone, or in addition to eyelid scrubs\/warm compresses, reduced clinical signs and symptoms, and tear proinflammatory cytokine levels. Overall, LE was safe and well tolerated, with minimal effects on IOP. While larger and longer-term studies are warranted, these data support the use of LE as a safe and effective treatment option for DED.<\/jats:p>","DOI":"10.1089\/jop.2020.0014","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T11:29:26Z","timestamp":1589196566000},"page":"497-511","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":44,"title":["Loteprednol Etabonate for the Treatment of Dry Eye Disease"],"prefix":"10.1177","volume":"36","author":[{"given":"Kenneth","family":"Beckman","sequence":"first","affiliation":[{"name":"Comprehensive Eyecare of Central Ohio, Westerville, Ohio, USA."},{"name":"Department of Ophthalmology, Ohio State University, Columbus, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Katz","sequence":"additional","affiliation":[{"name":"The Midwest Center for Sight, Des Plaines, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parag","family":"Majmudar","sequence":"additional","affiliation":[{"name":"Chicago Cornea Consultants, Hoffman Estates, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Rostov","sequence":"additional","affiliation":[{"name":"Northwest Eye Surgeons, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,9,7]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.008"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.011"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.icu.0000512373.81749.b7"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.003"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2017.06.033"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.01.026"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S188314"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-0919-7"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-19419"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40135-013-0009-1"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2015.11.002"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.006"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2019.02.012"},{"key":"e_1_3_4_15_2","unstructured":"Restasis\u00ae [package insert]. Irvine CA: Allergan; 2019."},{"key":"e_1_3_4_16_2","unstructured":"Cequa\u2122 [package insert]. Cranbury NJ: Sun Pharmaceutical Industries Inc.; 2018."},{"key":"e_1_3_4_17_2","unstructured":"Xiidra\u00ae [package insert]. Lexington MA: Shire US Inc.; 2017."},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.015"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.08.001"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.09.025"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.5.10.2099"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S30261"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000049"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-015-0122-z"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225010-00004"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(91)90120-T"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015849132396"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(82)91008-2"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(99)00040-1"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0315-8"},{"key":"e_1_3_4_31_2","first-page":"1082","article-title":"Assessment of ophthalmic steroid class adverse event reports for loteprednol etabonate","volume":"58","author":"Cavet M.E.","year":"2017","unstructured":"Cavet M.E., , Sanfilippo C.M., , and DeCory H.H. Assessment of ophthalmic steroid class adverse event reports for loteprednol etabonate. Invest. Ophthalmol. Vis. Sci. 58:1082, 2017.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_4_32_2","unstructured":"Alrex\u00ae [package insert]. Bridgewater NJ: Bausch\u2009+\u2009Lomb; 2019."},{"key":"e_1_3_4_33_2","unstructured":"Lotemax\u00ae [package insert]. Bridgewater NJ; Bausch\u2009+\u2009Lomb; 2016."},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1439920"},{"key":"e_1_3_4_35_2","unstructured":"United States Food and Drug Administration. Drug approval package. 2012. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202872_lotemax_toc.cfm Accessed August13 2019."},{"key":"e_1_3_4_36_2","unstructured":"Lotemax\u00ae gel [package insert]. Bridgewater NJ: Bausch\u2009+\u2009Lomb; 2018."},{"key":"e_1_3_4_37_2","first-page":"299","article-title":"Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop","volume":"7","author":"Coffey M.J.","year":"2013","unstructured":"Coffey M.J., , DeCory H.H., , and Lane S.S. Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop. Clin. Ophthalmol. 7:299\u2013312, 2013.","journal-title":"Clin. Ophthalmol"},{"key":"e_1_3_4_38_2","first-page":"1525","article-title":"Viscoelastic and dissolution characterization of submicron loteprednol etabonate ophthalmic gel, 0.38%","volume":"56","author":"Phillips E.","year":"2015","unstructured":"Phillips E., , Coffey M.J., , and Shawer M. Viscoelastic and dissolution characterization of submicron loteprednol etabonate ophthalmic gel, 0.38%. Invest. Ophthalmol. Vis. Sci. 56:1525, 2015.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_4_39_2","first-page":"S215","article-title":"Innovations in topical ocular corticosteroid therapy for the management of postoperative ocular inflammation and pain","volume":"25","author":"Salinger C.L.","year":"2019","unstructured":"Salinger C.L., , Gaynes B.I., , and Rajpal R.K. Innovations in topical ocular corticosteroid therapy for the management of postoperative ocular inflammation and pain. Am. J. Manag. Care. 25(12 Suppl):S215\u2013S226, 2019.","journal-title":"Am. J. Manag. Care"},{"key":"e_1_3_4_40_2","unstructured":"Inveltys\u00ae [package insert]. Waltham MA: Kala Pharmaceuticals; 2020."},{"key":"e_1_3_4_41_2","unstructured":"Kala Pharmaceuticals. Press release. Kala Pharmaceuticals announces FDA approval of INVELTYS\u2122 for the treatment of post-operative inflammation and pain following ocular surgery. August 23 2018. Available at: http:\/\/investors.kalarx.com\/node\/7301\/pdf Accessed September9 2019."},{"key":"e_1_3_4_42_2","unstructured":"Lotemax\u00ae SM [package insert]. Bridgewater NJ: Bausch\u2009+\u2009Lomb; 2019."},{"key":"e_1_3_4_43_2","unstructured":"Bausch\u2009+\u2009Lomb. Press release. Bausch\u2009+\u2009Lomb announces FDA approval of Lotemax\u00ae SM (loteprednol etabonate ophthalmic gel) 0.38% for the treatment of postoperative inflammation and pain following ocular surgery. Designed with SM technology for efficient penetration at a low preservative (BAK) level. Available at: https:\/\/www.bausch.com\/our-company\/recent-news\/artmid\/11336\/articleid\/508\/2252019-monday Accessed August13 2019."},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2018.0136"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.3109\/02713689109020329"},{"key":"e_1_3_4_46_2","first-page":"1980","article-title":"Ocular pharmacokinetics of loteprednol etabonate following ocular administration of a novel ointment formulation or a suspension (Lotemax\u00ae) in rabbits with corneal inflammation","volume":"51","author":"Glogowski S.","year":"2010","unstructured":"Glogowski S., , and Proksch J.W. Ocular pharmacokinetics of loteprednol etabonate following ocular administration of a novel ointment formulation or a suspension (Lotemax\u00ae) in rabbits with corneal inflammation. Invest. Ophthalmol. Vis. Sci. 51:1980, 2010.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2013.0142"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.04.052"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000000600"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.4068\/cmj.2015.51.1.26"},{"key":"e_1_3_4_51_2","first-page":"3826","article-title":"The effect of tapered small dose steroidal treatment on symptoms, clinical signs, and ocular surface inflammation in patients with dry eye syndrome","volume":"52","author":"Barabino S.","year":"2011","unstructured":"Barabino S., , Montaldo E., , Corsi E., et al. The effect of tapered small dose steroidal treatment on symptoms, clinical signs, and ocular surface inflammation in patients with dry eye syndrome. Invest. Ophthalmol. Vis. Sci. 52:3826, 2011.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_4_52_2","first-page":"97","article-title":"Is there a role for a long term tapered small dose steroidal treatment for keratoconjunctivitis sicca?","volume":"49","author":"Rolando M.","year":"2008","unstructured":"Rolando M., , Solignani F., , Valente C., , Allavena F., , Bertolotto M., , and Barabino S. Is there a role for a long term tapered small dose steroidal treatment for keratoconjunctivitis sicca?. Invest. Ophthalmol. Vis. Sci. 49:97, 2008.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.07.048"},{"key":"e_1_3_4_54_2","first-page":"142","article-title":"Study on the treatment of dry eye with loteprednol etabonate [in Chinese]","volume":"48","author":"Wan P.X.","year":"2012","unstructured":"Wan P.X., , Wang X.R., , Song Y.Y., et al. Study on the treatment of dry eye with loteprednol etabonate [in Chinese]. Zhonghua Yan Ke Za Zhi. 48:142\u2013147, 2012.","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000436"},{"key":"e_1_3_4_56_2","unstructured":"Evans D.G. Sheppard J.D. and Williams J.I. Loteprednol Etabonate Ophthalmic Gel 0.5% for Inflammation Associated with Dry Eye Disease: Outcomes Of a 12-Week Phase 2 Clinical Study. Presented at the Annual Meeting of the American Optometric Association; Washington DC: June 21\u201325 2017."},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2010.0085"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.4103\/tjo.tjo_15_18"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.08.015"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.213"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.11.006"},{"key":"e_1_3_4_62_2","unstructured":"Opitz D.L. Evola C. Paradesi A. Okaj E. et al. Efficacy of loteprednol etabonate ophthalmic gel 0.5% for the treatment of evaporative dry eye and meibomian gland dysfunction. Presented at the American Academy of Optometry. New Orleans LA; October 7\u201310 2015."},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.009"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.09.046"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2009.12.010"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S211611"},{"key":"e_1_3_4_67_2","unstructured":"Kala Pharmaceuticals. Press release. Kala Pharmaceuticals receives FDA complete response letter for KPI-121 0.25% NDA and plans to respond with data from STRIDE 3 trial. August 8 2019. Available at: http:\/\/investors.kalarx.com\/node\/7841\/pdf Accessed September11 2019."}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2020.0014","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0014","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:43:59Z","timestamp":1777646639000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2020.0014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,9,1]]}},"alternative-id":["10.1089\/jop.2020.0014"],"URL":"https:\/\/doi.org\/10.1089\/jop.2020.0014","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]}}}